Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L22 pseudogene 19 (RPL22P19) is a processed pseudogene, meaning it is a non-functional genomic sequence that resembles the ribosomal protein L22 (RPL22) gene but does not code for a functional protein. Pseudogenes like RPL22P19 are common for ribosomal proteins, which often have multiple processed pseudogenes spread throughout the genome[1][4]. RPL22P19 is cataloged in genomic databases but is not a therapeutic target or associated with biological functions or disease directly. In contrast, the functional ribosomal protein L22 is a component of the 60S ribosomal subunit with roles in protein synthesis and, secondarily, in diseases such as cancer, but these properties do not extend to its pseudogenes[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L22 pseudogene 19 (RPL22P19).